Emergency Pathway Cleared for Sublingual Ketamine in Military Pain Treatment
The secretaries of health and defense issued an emergency declaration enabling a potential expedited authorization for iX Biopharma's sublingual ketamine product, Wafermine, to treat acute pain in service members. The move follows a $41 million sole-source contract from the Defense Department, which is funding an ongoing phase III trial. Critics, including a former defense health official, are calling for transparency and scrutiny of the unusual emergency use pathway and contract award.
The Federal Register notice establishes a mechanism for emergency use authorization but does not itself grant approval; the FDA must still review any application against statutory standards. This pathway has been invoked only once before, in 2018 during the first Trump administration. The $41 million contract was structured as an "Other Transaction Agreement," a flexible procurement vehicle that federal law nonetheless directs should use competitive procedures whenever possible.
Ketamine's established battlefield role includes intravenous, intramuscular, and intranasal delivery, with advantages over opioids including less respiratory depression and better hemodynamic stability in casualties with hemorrhage or shock. The sublingual formulation, however, remains less studied, and its metabolic profile may require higher dosing — making the ongoing phase III trial results particularly significant for evaluating its safety and efficacy.
This development could reshape how military medical countermeasures are authorized, potentially setting precedent for accelerated approval pathways in future emergencies. Service members would be primary beneficiaries if the drug proves effective, gaining a portable, needle-free pain option for battlefield settings. However, the unusual contracting and approval process may raise questions about transparency in defense procurement, affecting public trust in military health systems and emergency drug authorization. The outcome could influence how future emergency declarations are used for pharmaceutical development.